中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(8): 1643-1648

Current status and reflections on the prevention and treatment of metabolic associated fatty liver disease through different fasting patterns

DOI: 10.12449/JCH250826
  • 1.

    The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450000，China

  • 2.

    Department of Spleen，Stomach，Liver and Gallbladder，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China

Research funding:

The Second National Famous Traditional Chinese Medicine Inheritance Studio Construction Project (National Medical Office Education Letter［2022］ No.245);

Funding Project for the Second Batch of Top Talents in the Inheritance and Innovation Talent Program of Traditional Chinese Medicine in Henan Province (Yu Health Commission TCM Letter ［2021］ No.15);

Special Project of Traditional Chinese Medicine Scientific Research in Henan Province (2023ZXZX1061);

Scientific Research Project of the “First-Rate Universities and Disciplines” of Traditional Chinese Medicine in Henan Province (HSRP-DFCTCM-2023-6-02)

More Information
  • Corresponding author: ZHAO Wenxia， zhao-wenxia@163.com （ORCID： 0000-0002-0592-3504）; LIU Xiaoyan， liuxiaoyan0917@126.com （ORCID： 0009-0002-7347-9318）
  • Received Date: 2024-12-02
  • Accepted Date: 2025-01-03
  • Published Date: 2025-08-25
    Abstract
  • The incidence rate of metabolic associated fatty liver disease （MAFLD） is gradually increasing， and it has become a common chronic liver disease globally. MAFLD is closely associated with metabolic dysfunction， with dietary and exercise interventions as the primary treatment method， among which dietary control is of particular importance. This article summarizes related articles on the prevention and treatment of MAFLD through different fasting patterns in recent years， and the analysis showed that by restricting food intake and controlling calorie consumption， fasting therapy can help to reduce body weight and improve metabolic disorders. Further studies and clinical practice are needed to explore and validate the value of different fasting patterns in the prevention and treatment of MAFLD.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    CHAN KE, KOH TJL, TANG ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10 739 607 individuals[J]. J Clin Endocrinol Metab, 2022, 107( 9): 2691- 2700. DOI: 10.1210/clinem/dgac321.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic)fatty liver disease(Version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
    [3]
    RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79( 6): 1542- 1556. DOI: 10.1016/j.jhep.2023.06.003.
    [4]
    TARGHER G, TILG H, BYRNE CD. Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach[J]. Lancet Gastroenterol Hepatol, 2021, 6( 7): 578- 588. DOI: 10.1016/S2468-1253(21)00020-0.
    [5]
    KOPPOLD DA, BREINLINGER C, HANSLIAN E, et al. International consensus on fasting terminology[J]. Cell Metab, 2024, 36( 8): 1779- 1794. e 4. DOI: 10.1016/j.cmet.2024.06.013.
    [6]
    HABIBULLAH M, JEMMIEH K, OUDA A, et al. Metabolic-associated fatty liver disease: A selective review of pathogenesis, diagnostic approaches, and therapeutic strategies[J]. Front Med(Lausanne), 2024, 11: 1291501. DOI: 10.3389/fmed.2024.1291501.
    [7]
    LEE J, AN HS, SHIN HJ, et al. Intermittent fasting reduces neuroinflammation and cognitive impairment in high-fat diet-fed mice by downregulating lipocalin-2 and galectin-3[J]. Nutrients, 2024, 16( 1): 159. DOI: 10.3390/nu16010159.
    [8]
    LIU XL, ZHANG Y, MA CY, et al. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling[J]. Mol Biol Rep, 2022, 49( 4): 3113- 3122. DOI: 10.1007/s11033-022-07142-5.
    [9]
    PATEL S, YAN ZH, REMEDI MS. Intermittent fasting protects β-cell identity and function in a type-2 diabetes model[J]. Metabolism, 2024, 153: 155813. DOI: 10.1016/j.metabol.2024.155813.
    [10]
    WILSON RB, ZHANG R, CHEN YJ, et al. Two-week isocaloric time-restricted feeding decreases liver inflammation without significant weight loss in obese mice with non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2020, 21( 23): 9156. DOI: 10.3390/ijms21239156.
    [11]
    YANG WW, CAO M, MAO XD, et al. Alternate-day fasting protects the livers of mice against high-fat diet-induced inflammation associated with the suppression of Toll-like receptor 4/nuclear factor κB signaling[J]. Nutr Res, 2016, 36( 6): 586- 593. DOI: 10.1016/j.nutres.2016.02.001.
    [12]
    ZHAO CL, ZHOU C, SHANG DF, et al. Influence of white fat browning on nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 4): 909- 914. DOI: 10.3969/j.issn.1001-5256.2023.04.025.

    赵晨露, 周铖, 尚东方, 等. 白色脂肪棕色化对非酒精性脂肪性肝病的影响[J]. 临床肝胆病杂志, 2023, 39( 4): 909- 914. DOI: 10.3969/j.issn.1001-5256.2023.04.025.
    [13]
    ZHU XJ, WANG XR, WANG JG, et al. Intermittent fasting-induced Orm2 promotes adipose browning via the GP130/IL23R-p38 cascade[J]. Adv Sci(Weinh), 2024, 11( 42): e2407789. DOI: 10.1002/advs.202407789.
    [14]
    YANG YZ, LIU DX. Impacts of time-restricted feeding on middle-aged and old mice with obesity[J]. J Physiol, 2024, 602( 22): 6109- 6123. DOI: 10.1113/JP285462.
    [15]
    MADDINENI G, OBULAREDDY SJ, PALADIYA RD, et al. The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: An in-depth umbrella review of meta-analyses with grade assessment[J]. Ann Med Surg(Lond), 2024, 86( 8): 4714- 4731. DOI: 10.1097/MS9.0000000000002276.
    [16]
    LI GL, XIE C, LU SY, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota[J]. Cell Metab, 2017, 26( 4): 672- 685. e 4. DOI: 10.1016/j.cmet.2017.08.019.
    [17]
    LIU ZG, DAI XS, ZHANG HB, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment[J]. Nat Commun, 2020, 11( 1): 855. DOI: 10.1038/s41467-020-14676-4.
    [18]
    MA RX, HU JQ, FU W, et al. Intermittent fasting protects against food allergy in a murine model via regulating gut microbiota[J]. Front Immunol, 2023, 14: 1167562. DOI: 10.3389/fimmu.2023.1167562.
    [19]
    GALLUZZI L, BAEHRECKE EH, BALLABIO A, et al. Molecular definitions of autophagy and related processes[J]. EMBO J, 2017, 36( 13): 1811- 1836. DOI: 10.15252/embj.201796697.
    [20]
    LI DZ, DUN YS, QI DK, et al. Intermittent fasting activates macrophage migration inhibitory factor and alleviates high-fat diet-induced nonalcoholic fatty liver disease[J]. Sci Rep, 2023, 13: 13068. DOI: 10.1038/s41598-023-40373-5.
    [21]
    KIM KE, SHIN HJ, JU Y, et al. Intermittent fasting attenuates metabolic-dysfunction-associated steatohepatitis by enhancing the hepatic autophagy-lysosome pathway[J]. Nutrients, 2023, 15( 21): 4574. DOI: 10.3390/nu15214574.
    [22]
    KETTNER NM, VOICU H, FINEGOLD MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis[J]. Cancer Cell, 2016, 30( 6): 909- 924. DOI: 10.1016/j.ccell.2016.10.007.
    [23]
    CHAIX A, LIN T, LE HD, et al. Time-restricted feeding prevents obesity and metabolic syndrome in mice lacking a circadian clock[J]. Cell Metab, 2019, 29( 2): 303- 319. e 4. DOI: 10.1016/j.cmet.2018.08.004.
    [24]
    LIN XZ, ZHU X, XIN Y, et al. Intermittent fasting alleviates non-alcoholic steatohepatitis by regulating bile acid metabolism and promoting fecal bile acid excretion in high-fat and high-cholesterol diet fed mice[J]. Mol Nutr Food Res, 2023, 67( 14): e2200595. DOI: 10.1002/mnfr.202200595.
    [25]
    ZHANG WT, WANG J, WANG LF, et al. Alternate-day fasting prevents non-alcoholic fatty liver disease and working memory impairment in diet-induced obese mice[J]. J Nutr Biochem, 2022, 110: 109146. DOI: 10.1016/j.jnutbio.2022.109146.
    [26]
    KORD-VARKANEH H, SALEHI-SAHLABADI A, TINSLEY GM, et al. Effects of time-restricted feeding(16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial[J]. Nutrition, 2023, 105: 111847. DOI: 10.1016/j.nut.2022.111847.
    [27]
    EZPELETA M, GABEL K, CIENFUEGOS S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial[J]. Cell Metab, 2023, 35( 1): 56- 70. e 3. DOI: 10.1016/j.cmet.2022.12.001.
    [28]
    CAI H, QIN YL, SHI ZY, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial[J]. BMC Gastroenterol, 2019, 19( 1): 219. DOI: 10.1186/s12876-019-1132-8.
    [29]
    PARVARESH A, RAZAVI R, ABBASI B, et al. Modified alternate-day fasting vs. calorie restriction in the treatment of patients with metabolic syndrome: A randomized clinical trial[J]. Complement Ther Med, 2019, 47: 102187. DOI: 10.1016/j.ctim.2019.08.021.
    [30]
    MAIFELD A, BARTOLOMAEUS H, LÖBER U, et al. Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients[J]. Nat Commun, 2021, 12( 1): 1970. DOI: 10.1038/s41467-021-22097-0.
    [31]
    HOLMER M, LINDQVIST C, PETERSSON S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet-a randomised controlled trial[J]. JHEP Rep, 2021, 3( 3): 100256. DOI: 10.1016/j.jhepr.2021.100256.
    [32]
    GAO YF, TSINTZAS K, MACDONALD IA, et al. Effects of intermittent(5∶2) or continuous energy restriction on basal and postprandial metabolism: A randomised study in normal-weight, young participants[J]. Eur J Clin Nutr, 2022, 76( 1): 65- 73. DOI: 10.1038/s41430-021-00909-2.
    [33]
    EKBERG NR, HELLBERG A, SUNDQVIST ML, et al. The 5‍∶‍2 diet affects markers of insulin secretion and sensitivity in subjects with and without type 2 diabetes-a non-randomized controlled trial[J]. Int J Mol Sci, 2024, 25( 17): 9731. DOI: 10.3390/ijms25179731.
    [34]
    WANG YY, TIAN F, QIAN XL, et al. Effect of 5∶‍2 intermittent fasting diet versus daily calorie restriction eating on metabolic-associated fatty liver disease-a randomized controlled trial[J]. Front Nutr, 2024, 11: 1439473. DOI: 10.3389/fnut.2024.1439473.
    [35]
    KAPOGIANNIS D, MANOLOPOULOS A, MULLINS R, et al. Brain responses to intermittent fasting and the healthy living diet in older adults[J]. Cell Metab, 2024, 36( 8): 1668- 1678. e 5. DOI: 10.1016/j.cmet.2024.05.017.
    [36]
    FEEHAN J, MACK A, TUCK C, et al. Time-restricted fasting improves liver steatosis in non-alcoholic fatty liver disease-a single blinded crossover trial[J]. Nutrients, 2023, 15( 23): 4870. DOI: 10.3390/nu15234870.
    [37]
    KHAN MN, KHAN SI, RANA MI, et al. Intermittent fasting positively modulates human gut microbial diversity and ameliorates blood lipid profile[J]. Front Microbiol, 2022, 13: 922727. DOI: 10.3389/fmicb.2022.922727.
    [38]
    KRAMER CK, ZINMAN B, FEIG DS, et al. Effect of time-restricted eating on β-cell function in adults with type 2 diabetes[J]. J Clin Endocrinol Metab, 2025, 110( 6): e2045- e2053. DOI: 10.1210/clinem/dgae594.
    [39]
    AKASHEH RT, ANKIREDDY A, GABEL K, et al. Effect of time-restricted eating on circulating levels of IGF1 and its binding proteins in obesity: An exploratory analysis of a randomized controlled trial[J]. Nutrients, 2024, 16( 20): 3476. DOI: 10.3390/nu16203476.
    [40]
    LI H, XIAO MZ, LI HF, et al. Expert consensus on fasting therapy in traditional Chinese medicine(draft for comment), 1st edition, 2019[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 6): 577- 580.

    李辉, 肖明中, 李恒飞, 等. 中医禁食疗法专家共识(征求意见稿)2019年第1版[J]. 中西医结合肝病杂志, 2019, 29( 6): 577- 580.
    [41]
    ZHANG JJ, HUANG YJ, KE B, et al. Effect of alternate- day- fasting therapy combined with Ling-Gui-Zhu-Gan(LGZG) decoction on hepatic oxidative stress in hyperlipidemic rat[J]. Lishizhen Med Mater Med Res, 2014, 25( 7): 1786- 1789. DOI: 10.3969/j.issn.1008-0805.2014.07.108.

    张俊杰, 黄颖娟, 柯斌, 等. 隔日禁食疗法联合苓桂术甘汤对高脂血症大鼠肝脏氧化应激的实验研究[J]. 时珍国医国药, 2014, 25( 7): 1786- 1789. DOI: 10.3969/j.issn.1008-0805.2014.07.108.
    [42]
    ZHANG Y, LUO JX, YANG F, et al. Effect of alternate-day fasting combined with Jijibigu prescription on liver oxidative stress and insulin receptor substrate 2 in rats with nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 10): 905- 908.

    张扬, 骆建兴, 杨芳, 等. 隔日禁食结合济饥辟谷方对NAFLD大鼠肝脏氧化应激及IRS 2的影响[J]. 中西医结合肝病杂志, 2021, 31( 10): 905- 908.
    [43]
    SHI L, KE B, YANG YB, et al. Effects of modified Linggui Zhugan decoction combined with dietary restrictions on PI3K/Akt/mTOR pathway in hippocampus of rats with spleen deficiency and phlegm dampness-induced diabetic encephalopathy[J]. J Chin Med Mater, 2018, 41( 5): 1186- 1190. DOI: 10.13863/j.issn1001-4454.2018.05.038.

    师林, 柯斌, 杨玉彬, 等. 加味苓桂术甘汤联合限食对脾虚痰湿型糖尿病脑病大鼠海马组织PI3K/Akt/mTOR通路的影响[J]. 中药材, 2018, 41( 5): 1186- 1190. DOI: 10.13863/j.issn1001-4454.2018.05.038.
    [44]
    LI H, QIN J. A new method to treat obesity and its metabolic complications: Fasting without hunger therapy[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28( 6): 321- 324. DOI: 10.3969/j.issn.1005-0264.2018.06.001.

    李辉, 秦鉴. 治疗肥胖及其代谢并发症的新方法—无饥饿禁食疗法[J]. 中西医结合肝病杂志, 2018, 28( 6): 321- 324. DOI: 10.3969/j.issn.1005-0264.2018.06.001.
    [45]
    SHEN WZ, LIAO SR, LIANG BJ, et al. Clinical study on weekend fasting joined with modified Linggui ZhuGan decoction in the treatment for non-alcoholic fatty liver disease[J]. West J Tradit Chin Med, 2020, 33( 3): 12- 16. DOI: 10.12174/j.issn.1004-6852.2020.03.04.

    沈维增, 廖圣榕, 梁炳君, 等. 周末禁食联合加味苓桂术甘汤治疗非酒精性脂肪肝病的临床研究[J]. 西部中医药, 2020, 33( 3): 12- 16. DOI: 10.12174/j.issn.1004-6852.2020.03.04.
    [46]
    ZHANG TY, LIU TL, HU JG, et al. Clinical effects of Chinese medicine fasting therapy in overweight/obese type 2 diabetes patients[J]. J Sun Yat Sen Univ Med Sci, 2022, 43( 4): 613- 620. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0412.

    张汀滢, 刘桃丽, 胡建国, 等. 中医禁食疗法对超重/肥胖2型糖尿病患者的临床疗效[J]. 中山大学学报(医学科学版), 2022, 43( 4): 613- 620. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0412.
    [47]
    ZHAO WX, YANG PW. Effect and mechanism of external therapy of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 10): 1942- 1948. DOI: 10.12449/JCH241003.

    赵文霞, 杨培伟. 中医外治疗法在非酒精性脂肪性肝病中的应用及其疗效机制[J]. 临床肝胆病杂志, 2024, 40( 10): 1942- 1948. DOI: 10.12449/JCH241003.
    [48]
    FEI JL, LIU ST, CHEN Q, et al. Clinical observation on treating obese nonalcoholic fatty liver disease by the Hufu Tongbian scraping with hunger-free fasting therapy[J]. Clin J Chin Med, 2022, 14( 23): 58- 61. DOI: 10.3969/j.issn.1674-7860.2022.23.017.

    费景兰, 刘素彤, 陈茜, 等. 虎符铜砭刮痧配合无饥饿禁食疗法治疗肥胖型非酒精性脂肪性肝病的临床观察[J]. 中医临床研究, 2022, 14( 23): 58- 61. DOI: 10.3969/j.issn.1674-7860.2022.23.017.
    [49]
    HUANG WX, LIU HS, LI F, et al. Clinical study on the treatment of simple obesity with deficiency of spleen and kidney by fasting therapy of traditional Chinese medicine combined with catgut embedding at acupoint[J]. J Shaanxi Univ Chin Med, 2022, 45( 6): 123- 127. DOI: 10.13424/j.cnki.jsctcm.2022.06.024.

    黄伟旋, 刘浩生, 李芳, 等. 中医禁食疗法联合穴位埋线治疗脾肾两虚型单纯性肥胖临床研究[J]. 陕西中医药大学学报, 2022, 45( 6): 123- 127. DOI: 10.13424/j.cnki.jsctcm.2022.06.024.
    [50]
    VARADY KA, CIENFUEGOS S, EZPELETA M, et al. Cardiometabolic benefits of intermittent fasting[J]. Annu Rev Nutr, 2021, 41: 333- 361. DOI: 10.1146/annurev-nutr-052020-041327.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (355) PDF downloads(38) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return